Compare Sirius XM Holdings Inc (SIRI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Viatris Inc — how do they compare? Sirius XM Holdings Inc trades at $26.71 (market cap $8.87B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.3× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and Viatris Inc for 57 Days on average.
| SIRI | VTRS | |
|---|---|---|
Market Cap | $8.87B | $20.03B |
Volume | 4,324,672 | 14,109,977 |
Sector | Media | Health |
52-Week High | $32.59 | $18.27 |
52-Week Low | $19.92 | $9.74 |
Typical Hold Time | 102 Days | 57 Days |
Enterprise Value | $18.16B | $32.15B |
Dividend Yield | 4.1% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.51, up 2.16% with mixed technical signals showing neutral momentum. The company demonstrates solid fundamentals with a P/E of 10.57 and P/B of 0.75, though recent earnings show volatility with two misses and one beat in the last four quarters. Strong cash flow generation and a new YouTube partnership provide growth catalysts, while high debt levels and competitive pressures remain concerns.
The stock presents a compelling value opportunity with analyst consensus pointing to 30% upside to the $34.43 price target. However, execution risks in advertising expansion and subscription growth, coupled with $10.31 billion in long-term debt, require careful monitoring. Recent institutional buying and positive management commentary suggest confidence in the company's strategic direction.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
